<DOC>
	<DOCNO>NCT02490111</DOCNO>
	<brief_summary>This study evaluate efficacy safety DWJ1319 prevention gallstone formation gastrectomy patient gastric cancer . Two-thirds participant receive DWJ1319 , receive placebo .</brief_summary>
	<brief_title>Clinical Trials Prevention Gallstone Formation After Gastrectomy Patient With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gallstones</mesh_term>
	<criteria>Male female least 19 year age Patient undergo gastrectomy ( total , distal proximal gastrectomy ) D1+ D2 lymph node dissection Performance status 0 1 ECOG ( Eastern Cooperative Oncology Group ) scale Written inform consent Patients cholangitis , cholecystitis , nonfunctional gall bladder , biliary obstruction Presence gallstone ultrasonography and/or CT History previous cholecystectomy Patients undergo pyloruspreserving gastrectomy Pregnant lactate woman fertile woman use proper contraceptive method Patients history drug alcohol abuse within 5 year ago</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>